ClinicalTrials.gg
CompletedNCT00276458Updated May 13, 2024Results posted

To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)

A Phase 3 interventional study of Comparator: atorvastatin and Comparator: Placebo in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-05-13.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
196
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
38th of 97
196 · median 148
Started
2006
with 5 others
Phase 3
50 of 98
1 open now
Registered
14th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 38th largest by enrollment of the 97 interventional ones that give a count, is one of 6 that started in 2006, is one of 50 in phase 3, and was the 14th registered.

Hypercholesterolemia

1,179 studies on the registry are indexed under Hypercholesterolemia; 96 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 57 Hypercholesterolemia studies recruiting now, 25 (44%) set no upper age limit and 20 (35%) stop at 75 or younger; 10 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate and compare the efficacy and safety of ezetimibe plus atorvastatin versus atorvastatin in hypercholesterolemic patients at moderately high risk for coronary heart disease not adequately controlled on atorvastatin 20 mg.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with LDL-C >100 mg/dL \& on a stable dose of atorvastatin 20 mg

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women or intending to become pregnant
  • Patient with sensitivity or intolerance to ezetimibe or atorvastatin
  • Patient with diabetes or coronary heart disease
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
196 participants (actual)

Study arms

  • Active comparator
    1

    Atorvastatin 40mg tablet + Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day).

    Drug: Comparator: atorvastatin · Drug: Comparator: Placebo

  • Experimental
    2

    Atorvastatin 40mg Pbo tablet + Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day).

    Drug: Comparator: ezetimibe · Drug: Comparator: Placebo.

Interventions

  • Atorvastatin 40mg tablet po qd (by mouth, once a day) for 6 weeks

  • DrugComparator: Placebo

    Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks

  • Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day). for 6 weeks.

  • DrugComparator: Placebo.

    Atorvastatin 40mg Pbo tablets po qd (by mouth, once a day). for 6 weeks.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6

    \[(6 week value - baseline value)/baseline value\]\*100%.

    Time frame: 6 weeks

Secondary outcomes

  1. Percent Change in High Density Lipoprotein -Cholesterol (HDL-C)at Week 6

    \[(6 week value - baseline value)/baseline value\]\*100%.

    Time frame: 6 weeks

  2. Percent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6

    \[(6 week value - baseline value)/baseline value\]\*100%.

    Time frame: 6 Weeks

  3. Percent Change From Baseline in Total-Cholesterol at Week 6

    (\[6 week value - baseline value)/baseline value\]\*100%.

    Time frame: 6 Weeks

  4. Percent Change From Baseline in Triglycerides (TG) at Week 6

    \[(6 week value - baseline value)/baseline value\]\*100%.

    Time frame: 6 weeks

  5. Percent Change From Baseline in Apolipoprotein B at Week 6

    \[(6 week value - baseline value)/baseline value\]\*100%.

    Time frame: 6 Weeks

  6. Percent Change From Baseline in Total-Cholesterol:High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6

    \[(6 week value - baseline value)/baseline value\]\*100%.

    Time frame: 6 Weeks

  7. Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6

    \[(6 week value - baseline value)/baseline value\]\*100%.

    Time frame: 6 Weeks

  8. Percent Change From Baseline in Apolipoprotein B: Apolipoprotein A-I Ratio at Week 6

    \[(6 week value - baseline value)/baseline value\]\*100%.

    Time frame: 6 Weeks

  9. Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6

    \[(6 week value - baseline value)/baseline value\]\*100%.

    Time frame: 6 Weeks

  10. Percent Change From Baseline in C-Reactive Protein (CRP) at Week 6

    \[(6 week value - baseline value)/baseline value\]\*100%.

    Time frame: 6 Weeks

  11. Number of Participants Who Attained Target LDL-C <100 mg/dL at Week 6

    Time frame: 6 weeks

07

Results

Posted Jul 8, 2009
Limitations and caveats
194 out of 196 randomized patients took at least one dose of blinded study therapy and were included in the safety analysis

Participant flow

Phase III First Patient In: 4/5/2006; Last Patient Last Visit 1/17/2008 72 centers worldwide (US, Canada, Austria, Costa Rica) Eligible patients include those on a stable dose of atorvastatin 20 mg; or patients with adjusted LDL-C pre-screen ranges who were treated with other lipid modifying therapy, or were statin and/or ezetimibe naïve.

Participant flow — Overall Study
MilestoneAtorvastatin + EzetimibeAtorvastatin
Started9898
Completed9291
Not completed67
Withdrew: Adverse event02
Withdrew: Lost to follow-up22
Withdrew: Protocol violation43

Outcome measures

PrimaryPercent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6

\[(6 week value - baseline value)/baseline value\]\*100%.

Time frame:
6 weeks
Reported as:
Least squares mean · Percent
Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6
PercentAtorvastatin + EzetimibeAtorvastatin
Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6-30.8 (-34.5 to -27.0)-10.9 (-14.7 to -7.1)
Statistical analysis
  • Atorvastatin + Ezetimibe vs Atorvastatin · ANCOVA · p = <0.001 · Mean difference (final values): -19.9 · 95% CI -25.2 to -14.5(Atorva + EZ minus Atorva)
SecondaryPercent Change in High Density Lipoprotein -Cholesterol (HDL-C)at Week 6

\[(6 week value - baseline value)/baseline value\]\*100%.

Time frame:
6 weeks
Reported as:
Least squares mean · Percent
Percent Change in High Density Lipoprotein -Cholesterol (HDL-C)at Week 6
PercentAtorvastatin + EzetimibeAtorvastatin
Percent Change in High Density Lipoprotein -Cholesterol (HDL-C)at Week 63.2 (0.2 to 6.2)0.8 (-2.2 to 3.8)
Statistical analysis
  • Atorvastatin + Ezetimibe vs Atorvastatin · ANCOVA · p = 0.273 · Mean difference (final values): 2.4 · 95% CI -1.9 to 6.6(Atorva + EZ minus Atorva)
SecondaryPercent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6

\[(6 week value - baseline value)/baseline value\]\*100%.

Time frame:
6 Weeks
Reported as:
Least squares mean · Percent
Percent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6
PercentAtorvastatin + EzetimibeAtorvastatin
Percent Change in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 6-26.7 (-30.1 to -23.3)-10.2 (-13.6 to -6.9)
Statistical analysis
  • Atorvastatin + Ezetimibe vs Atorvastatin · ANCOVA · p = <0.001 · Mean difference (final values): -16.4 · 95% CI -21.2 to -11.7(Atorva + EZ minus Atorva)
SecondaryPercent Change From Baseline in Total-Cholesterol at Week 6

(\[6 week value - baseline value)/baseline value\]\*100%.

Time frame:
6 Weeks
Reported as:
Least squares mean · percent
Percent Change From Baseline in Total-Cholesterol at Week 6
percentAtorvastatin + EzetimibeAtorvastatin
Percent Change From Baseline in Total-Cholesterol at Week 6-19.7 (-22.2 to -17.1)-7.4 (-10.0 to -4.9)
Statistical analysis
  • Atorvastatin + Ezetimibe vs Atorvastatin · ANCOVA · p = <0.001 · Mean difference (final values): -12.2 · 95% CI -15.8 to -8.6(Atorva + EZ minus Atorva)
SecondaryPercent Change From Baseline in Triglycerides (TG) at Week 6

\[(6 week value - baseline value)/baseline value\]\*100%.

Time frame:
6 weeks
Reported as:
Least squares mean · Percent
Percent Change From Baseline in Triglycerides (TG) at Week 6
PercentAtorvastatin + EzetimibeAtorvastatin
Percent Change From Baseline in Triglycerides (TG) at Week 6-17.8 (-23.7 to -11.4)-5.5 (-14.4 to 0.0)
Statistical analysis
  • Atorvastatin + Ezetimibe vs Atorvastatin · Nonparametric ANCOVA · p = 0.159 (ANCOVA using ranks based on normal scores (Tukey method) with model terms for treatment and baseline triglycerides value) · Median difference (final values): -8.9 · 95% CI -17.7 to -0.4The median difference is based on the Hodges-Lehmann estimates of shift; The distribution-free 95% CI is based on Wilcoxon's rank sum test statistic. (Atorva + EZ minus Atorva)
SecondaryPercent Change From Baseline in Apolipoprotein B at Week 6

\[(6 week value - baseline value)/baseline value\]\*100%.

Time frame:
6 Weeks
Reported as:
Least squares mean · Percent
Percent Change From Baseline in Apolipoprotein B at Week 6
PercentAtorvastatin + EzetimibeAtorvastatin
Percent Change From Baseline in Apolipoprotein B at Week 6-21.4 (-24.3 to -18.5)-7.7 (-10.6 to -4.8)
Statistical analysis
  • Atorvastatin + Ezetimibe vs Atorvastatin · ANCOVA · p = <0.001 · Mean difference (final values): -13.7 · 95% CI -17.8 to -9.6(Atorva + EZ minus Atorva)
Post-hocPercent Change in Apolipoprotein A-I at Week 6

\[(6 week value - baseline value)/baseline value\]\*100%.

Time frame:
6 Weeks
Reported as:
Least squares mean · Percent
Percent Change in Apolipoprotein A-I at Week 6
PercentAtorvastatin + EzetimibeAtorvastatin
Percent Change in Apolipoprotein A-I at Week 6-1.9 (-4.2 to 0.4)-1.2 (-3.5 to 1.1)
Statistical analysis
  • Atorvastatin + Ezetimibe vs Atorvastatin · ANCOVA · p = 0.681 · Mean difference (final values): -0.7 · 95% CI -3.9 to 2.6(Atorva + EZ minus Atorva)
SecondaryPercent Change From Baseline in Total-Cholesterol:High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6

\[(6 week value - baseline value)/baseline value\]\*100%.

Time frame:
6 Weeks
Reported as:
Least squares mean · Percent
Percent Change From Baseline in Total-Cholesterol:High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
PercentAtorvastatin + EzetimibeAtorvastatin
Percent Change From Baseline in Total-Cholesterol:High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6-20.6 (-23.7 to -17.5)-7.5 (-10.6 to -4.4)
Statistical analysis
  • Atorvastatin + Ezetimibe vs Atorvastatin · ANCOVA · p = <0.001 · Mean difference (final values): -13.1 · 95% CI -17.5 to -8.7(Atorva + EZ minus Atorva)
SecondaryPercent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6

\[(6 week value - baseline value)/baseline value\]\*100%.

Time frame:
6 Weeks
Reported as:
Least squares mean · Percent
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
PercentAtorvastatin + EzetimibeAtorvastatin
Percent Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6-31.9 (-35.8 to -27.9)-11.0 (-14.9 to -7.0)
Statistical analysis
  • Atorvastatin + Ezetimibe vs Atorvastatin · ANCOVA · p = <0.001 · Mean difference (final values): -20.9 · 95% CI -26.5 to -15.3(Atorva + EZ minus Atorva)
SecondaryPercent Change From Baseline in Apolipoprotein B: Apolipoprotein A-I Ratio at Week 6

\[(6 week value - baseline value)/baseline value\]\*100%.

Time frame:
6 Weeks
Reported as:
Least squares mean · Percent
Percent Change From Baseline in Apolipoprotein B: Apolipoprotein A-I Ratio at Week 6
PercentAtorvastatin + EzetimibeAtorvastatin
Percent Change From Baseline in Apolipoprotein B: Apolipoprotein A-I Ratio at Week 6-19.0 (-22.3 to -15.6)-5.8 (-9.2 to -2.5)
Statistical analysis
  • Atorvastatin + Ezetimibe vs Atorvastatin · ANCOVA · p = <0.001 · Mean difference (final values): -13.1 · 95% CI -17.9 to -8.3(Atorva + EZ minus Atorva)
SecondaryPercent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6

\[(6 week value - baseline value)/baseline value\]\*100%.

Time frame:
6 Weeks
Reported as:
Least squares mean · Percent
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6
PercentAtorvastatin + EzetimibeAtorvastatin
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (HDL-C):High Density Lipoprotein Cholesterol (HDL-C) Ratio at Week 6-27.2 (-31.4 to -23.0)-9.9 (-14.1 to -5.7)
Statistical analysis
  • Atorvastatin + Ezetimibe vs Atorvastatin · ANCOVA · p = <0.001 · Mean difference (final values): -17.3 · 95% CI -23.2 to -11.4(Atorva + EZ minus Atorva)
SecondaryPercent Change From Baseline in C-Reactive Protein (CRP) at Week 6

\[(6 week value - baseline value)/baseline value\]\*100%.

Time frame:
6 Weeks
Reported as:
Least squares mean · percent
Percent Change From Baseline in C-Reactive Protein (CRP) at Week 6
percentAtorvastatin + EzetimibeAtorvastatin
Percent Change From Baseline in C-Reactive Protein (CRP) at Week 6-6.7 (-23.7 to 14.2)-9.2 (-25.8 to 11.1)
Statistical analysis
  • Atorvastatin + Ezetimibe vs Atorvastatin · Longitudinal Data Analysis (LDA) · p = 0.841 · Mean difference (final values): 2.5 · 95% CI -23.8 to 28.8Data for analysis was transformed by the natural log and the difference in geometric mean % change from BL calculated based on the difference in the back-transformed least squares means. (Atorva + EZ minus Atorva)
Post-hocPercent Change in C-Reactive Protein (CRP) at Week 6

\[(6 week value - baseline value)/baseline value\]\*100%.

Time frame:
6 weeks
Reported as:
Least squares mean · Percent
Percent Change in C-Reactive Protein (CRP) at Week 6
PercentAtorvastatin + EzetimibeAtorvastatin
Percent Change in C-Reactive Protein (CRP) at Week 6-19.2 (-25.0 to -4.0)-9.1 (-22.2 to 5.3)
Statistical analysis
  • Atorvastatin + Ezetimibe vs Atorvastatin · Nonparametric ANCOVA · p = 0.839 · Mean difference (final values): -8.3 · 95% CI -26.1 to 8.3The median difference is based on the Hodges-Lehmann estimates of shift; The distribution-free 95% CI is based on Wilcoxon's rank sum test statistic. (Atorva + EZ minus Atorva)
SecondaryNumber of Participants Who Attained Target LDL-C <100 mg/dL at Week 6
Time frame:
6 weeks
Reported as:
Number · Participants
Number of Participants Who Attained Target LDL-C <100 mg/dL at Week 6
ParticipantsAtorvastatin + EzetimibeAtorvastatin
<100 mg/dL7745
≥100 mg/dL1547
Statistical analysis
  • Atorvastatin + Ezetimibe vs Atorvastatin · Regression, Logistic · p = <0.001 · Odds ratio (or): 8.60 · 95% CI 3.80 to 19.47Estimated ratio is the predictive odds of attaining LDL-C target on Atorva + EZ versus Atorva.

Adverse events

Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Atorvastatin + Ezetimibe—0/96 (0%)17/96 (17.7%)
Atorvastatin—0/98 (0%)22/98 (22.4%)
Most frequent other events
Showing 10 of 32
Most frequent other events
EventAtorvastatin + EzetimibeAtorvastatin
VertigoEar and labyrinth disorders2/960/98
FatigueGeneral disorders2/961/98
NasopharyngitisInfections and infestations2/960/98
Irritable bowel syndromeGastrointestinal disorders0/962/98
Abdominal tendernessGastrointestinal disorders1/960/98
Chest DiscomfortGeneral disorders1/960/98
EdemaGeneral disorders1/960/98
GastroenteritisInfections and infestations1/961/98
Oral herpesInfections and infestations1/960/98
Upper respiratory tract infectionInfections and infestations1/960/98

Baseline characteristics

Age, Continuous
Age, Continuous(years)Atorvastatin + EzetimibeAtorvastatinTotal
Mean56.4 (24 to 78)58.0 (34 to 76)57.2 (24 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)Atorvastatin + EzetimibeAtorvastatinTotal
Female404989
Male5849107
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Atorvastatin + EzetimibeAtorvastatinTotal
White5860118
American Indian or Alaska Native101
Asian7815
Black3912
Multi-Racial292150
Apolipoprotein A-I
Apolipoprotein A-I(mg/dL)Atorvastatin + EzetimibeAtorvastatinTotal
Mean161.8 ± 25.2163.4 ± 24.6162.6 ± 24.8
Apolipoprotein A-I:Apolipoprotein B ratio
Apolipoprotein A-I:Apolipoprotein B ratio(Ratio)Atorvastatin + EzetimibeAtorvastatinTotal
Mean0.8 ± 0.20.7 ± 0.20.8 ± 0.2
Apolipoprotein B
Apolipoprotein B(mg/dL)Atorvastatin + EzetimibeAtorvastatinTotal
Mean122.9 ± 22.4119.9 ± 21.0121.4 ± 21.7
C Reactive Protein
C Reactive Protein(mg/dL)Atorvastatin + EzetimibeAtorvastatinTotal
Mean1.6 ± 2.61.2 ± 1.71.5 ± 2.1
High Density Lipoprotein (HDL)
High Density Lipoprotein (HDL)(mg/dL)Atorvastatin + EzetimibeAtorvastatinTotal
Mean51.1 ± 12.151.7 ± 11.551.4 ± 11.8

7 further baseline measures are reported on the registry.

08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Conard SE, Bays HE, Leiter LA, Bird SR, Rubino J, Lowe RS, Tomassini JE, Tershakovec AM. Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol. 2008 Dec 1;102(11):1489-94. doi: 10.1016/j.amjcard.2008.09.075. Epub 2008 Oct 23. PubMed 19026302 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Jan 2008 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2009, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2006
First posted
Jan 13, 2006
Start
Feb 2006
Primary completionActual
Jan 2008
CompletionActual
Jan 2008
Results first posted
Jul 8, 2009
Last update
May 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00276458
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jan 13, 2006
Start date
Feb 2006
Primary completion
Jan 2008
Completion
Jan 2008
Results posted
Jul 8, 2009
Last update
May 13, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ezetimibe

Start the discussion